For more than 25 years, Dr. Kathleen Anne Welsh-Bohmer’s research activities have been focused around developing effective prevention and treatment strategies to eliminate the onset of cognitive disorders occurring in later life. As one of the true leaders in Alzheimer’s Disease scientific research, Dr. Welsh-Bohmer brings vast expertise to her work with VeraSci. Through a special contract with Duke University Medical Center, Dr. Welsh-Bohmer serves as a distinguished scientific advisor for Neurodegenerative Disorders at VeraSci and leads a team of scientists and operational experts in developing new tools for assessing cognitive and clinical changes and supporting clinical trials in MCI, Alzheimer’s disease, and other neurological and age-related disorders.
Dr. Welsh-Bohmer’s prior work included oversight of the neuropsychology scientific operations of a Phase III global clinical trial to delay the onset of Alzheimer’s disease entitled the “TOMMORROW” study. Her current activities as a Professor of Psychiatry and Neurology within the Duke Clinical Research Institute (DCRI) center around developing methods to enhance early diagnosis and speed drug discovery in Alzheimer’s disease and related neurodegenerative conditions.
Therapeutic Focus: Preclinical Alzheimer’s Disease, Mild Cognitive Impairment, Alzheimer’s Disease Dementia, Cognitive Aging, Vascular Cognitive Impairment, Lewy Body Dementia, Frontotemporal Dementia